QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
NASDAQ:CVKD

Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

$0.61
-0.03 (-4.64%)
(As of 10:32 AM ET)
Today's Range
$0.60
$0.64
50-Day Range
$0.56
$1.82
52-Week Range
$0.40
$3.14
Volume
23,862 shs
Average Volume
348,496 shs
Market Capitalization
$9.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Cadrenal Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
473.5% Upside
$3.50 Price Target
Short Interest
Healthy
0.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Cadrenal Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

435th out of 939 stocks

Pharmaceutical Preparations Industry

204th out of 433 stocks

CVKD stock logo

About Cadrenal Therapeutics Stock (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

CVKD Stock Price History

CVKD Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cadrenal Therapeutics Inc CVKD
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics reports Q3 results
CVKD Cadrenal Therapeutics, Inc.
See More Headlines
Receive CVKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CVKD
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+446.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.59 per share

Miscellaneous

Free Float
6,704,000
Market Cap
$10.25 million
Optionable
Not Optionable
Beta
1.24
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

CVKD Stock Analysis - Frequently Asked Questions

Should I buy or sell Cadrenal Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CVKD shares.
View CVKD analyst ratings
or view top-rated stocks.

What is Cadrenal Therapeutics' stock price target for 2024?

2 analysts have issued twelve-month price objectives for Cadrenal Therapeutics' stock. Their CVKD share price targets range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 473.5% from the stock's current price.
View analysts price targets for CVKD
or view top-rated stocks among Wall Street analysts.

How have CVKD shares performed in 2024?

Cadrenal Therapeutics' stock was trading at $0.7399 at the beginning of 2024. Since then, CVKD stock has decreased by 17.5% and is now trading at $0.6103.
View the best growth stocks for 2024 here
.

Are investors shorting Cadrenal Therapeutics?

Cadrenal Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 21,900 shares, an increase of 204.2% from the February 29th total of 7,200 shares. Based on an average trading volume of 340,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the shares of the company are short sold.
View Cadrenal Therapeutics' Short Interest
.

When is Cadrenal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CVKD earnings forecast
.

When did Cadrenal Therapeutics IPO?

Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share.

Who are Cadrenal Therapeutics' major shareholders?

Cadrenal Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (3.18%). Insiders that own company stock include John Raymond Murphy and Quang X Pham.
View institutional ownership trends
.

How do I buy shares of Cadrenal Therapeutics?

Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVKD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners